German pharmaceuticals and agriculture group Bayer on Tuesday raised its 2026 profit outlook, citing stronger-than-expected performance in its pharmaceuticals business, which delivered sales above market estimates in the third quarter, Reuters reported.The company now expects adjusted core earnings, on a currency-adjusted basis, to reach between 9.8 billion euros and 10.3 billion euros in 2026. This compares with its previous forecast of 9.6 billion euros to 10.1 billion euros.Read more: Global Market Today: Asian stocks slide as US chip selloff deepensBayer's pharmaceuticals business reported third-quarter sales of 4.68 billion euros, beating analysts' expectations by 5%, according to a poll conducted by Vara Research.